Citi analyst Yigal Nochomovitz lowered the firm’s price target on Ovid Therapeutics to $3.50 from $4 and keeps a Neutral rating on the shares. The analyst updated the company’s model to include the Q4 results.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OVID:
- Ovid Therapeutics initiated with a Buy at B. Riley
- Ovid Therapeutics initiated with a Buy at H.C. Wainwright
- Krispy Kreme upgraded, Altice USA downgraded: Wall Street’s top analyst calls
- Ovid initiated with Outperform on ‘unique’ assets at Wedbush
- Ovid Therapeutics initiated with an Outperform at Wedbush
